The well known organization called the Medistem Laboratories or the MDSM based at Phoenix in Ariz through its latest press declaration has confirmed about the completion of the preclinical proof-of-concept studies that has been highly successful in the demonstration of the positive potential of its MDS-786 candidate drug that has been specially made and prescribed for lung cancer. It is at the International Society for Cellular Therapy meeting in Sydney, Australia that the findings were presented. It has been noted in this respect, that the very presentation reviewed the aptitude of MDS-786 to bring about a process called "differentiation", where it has been displayed that the tumor cells are won over through the mere transformation into the non-tumor cells and it is through the effective utilization of a placentally derived product.

It is true that there have been several preclinical investigations but according to the esteemed views of the researchers, engaged in the present study the findings have been truly prolific. In this respect here have been a series of discussions among the present correspondent and the key persons of the investigative study mission for ascertaining the true picture. According to Dr. Thomas Ichim, the venerated Chief of Scientific Development of the Medistem Laboratories and also the most important author of the paper, entitled "Differentiation and Inhibition of Tumor Cells by Cord Blood Stem Cells said, "To date, treatment options for patients with lung cancer are primarily limited to highly toxic chemotherapy and radiotherapy approaches, which in many cases are not successful. Through harnessing molecular mechanisms that signal stem cell maturation in normal cells, we are inducing a process that drives malignant cells to convert into non-malignant cells. He also went ion saying, "The process of inducing malignant cells to transform into normal cells has been proven clinically as a viable treatment for cancer and is used in the treatment of patients with acute promyelocytic leukemia. By applying such a process to solid tumors, we believe numerous therapeutic applications may exist that lack the toxicity of current approaches."

There are no doubt several viable options in the contemporary age for the mere treatment of some forms of cancer, but this hope has been expressed on the part of the Medistem that MDS-786 has enough potential to initiate and address this dreaded disease in a non-toxic manner just through the process of giving consent to the stem cells and the immune system so as to work in concert with one another to achieve homeostasis.